Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism

Overview

Journal Indian J Clin Biochem

Specialty Biochemistry

Date 2015 Jun 20

PMID 26089623

Citations 4

Authors

S Suresh

T Vijayakumar

Affiliations

Soon will be listed here.

Abstract

Functional ovarian hyperandrogenism (FOH) is a form of polycystic ovary syndrome (PCOS) characterized by elevated circulating levels of androgens derived from the ovary. Insulin resistance (IR) is the most common etiological factor in women with FOH. IR causes the generation of increased oxidative stress (OS) and diminished antioxidant status. OS is directly correlated with both IR and testosterone levels, which consequently contribute to endocrine and biochemical alterations in FOH women. In the current study, elevations in total testosterone, free testosterone and luteinizing hormone (LH) levels accompanied by a decrease in follicle stimulating hormone (FSH) level leading to higher LH:FSH ratio were the prominent endocrine changes observed in women with FOH. A significant increase in fasting blood levels of glucose and insulin, as well as an elevated IR were also seen in FOH women, as compared to their age matched controls. Women with FOH have higher pro-oxidant and lower anti-oxidant levels in blood than their age matched controls. In FOH women, elevations in LH:FSH ratio and OS are correlated more with hyperandrogenemia than with IR. Of the androgens, free rather than total testosterone has better positive correlations with elevated LH:FSH ratio and OS, and hence, the former is a better predictive marker for the development of biochemical PCOS in women with FOH.

Citing Articles

Free androgen index (FAI)'s relations with oxidative stress and insulin resistance in polycystic ovary syndrome.

Rahmatnezhad L, Moghaddam-Banaem L, Behrouzi Lak T, Shiva A, Rasuli J Sci Rep. 2023; 13(1):5118.

PMID: 36991023 PMC: 10060256. DOI: 10.1038/s41598-023-31406-0.

Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis.

Beitl K, Dewailly D, Seemann R, Hager M, Bunker J, Mayrhofer D Front Endocrinol (Lausanne). 2022; 13:904706.

PMID: 35721741 PMC: 9201247. DOI: 10.3389/fendo.2022.904706.

Evaluation of Changes in Levels of Hyperandrogenism, Hirsutism and Menstrual Regulation After a Period of Aquatic High Intensity Interval Training in Women with Polycystic Ovary Syndrome.

Samadi Z, Bambaeichi E, Valiani M, Shahshahan Z Int J Prev Med. 2019; 10:187.

PMID: 31807257 PMC: 6852193. DOI: 10.4103/ijpvm.IJPVM_360_18.

Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy.

Yao K, Bian C, Zhao X Exp Ther Med. 2017; 14(2):1271-1276.

PMID: 28810587 PMC: 5526116. DOI: 10.3892/etm.2017.4642.

References

Norman R, Dewailly D, Legro R, Hickey T . Polycystic ovary syndrome. Lancet. 2007; 370(9588):685-97. DOI: 10.1016/S0140-6736(07)61345-2. View

Verit F, Erel O . Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008; 65(4):233-9. DOI: 10.1159/000113046. View

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2008; 91(2):456-88. DOI: 10.1016/j.fertnstert.2008.06.035. View

Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I . Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest. 2011; 35(3):317-21. DOI: 10.3275/7682. View

Siklar Z, Ocal G, Adiyaman P, Ergur A, Berberoglu M . Functional ovarian hyperandrogenism and polycystic ovary syndrome in prepubertal girls with obesity and/or premature pubarche. J Pediatr Endocrinol Metab. 2007; 20(4):475-81. DOI: 10.1515/jpem.2007.20.4.475. View

Sakumoto T, Tokunaga Y, Tanaka H, Nohara M, Motegi E, Shinkawa T . Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women. Reprod Med Biol. 2018; 9(4):185-190. PMC: 5904600. DOI: 10.1007/s12522-010-0062-5. View

Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View

Bhasin S, Cunningham G, Hayes F, Matsumoto A, Snyder P, Swerdloff R . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536-59. DOI: 10.1210/jc.2009-2354. View

Gambineri A, Patton L, Prontera O, Fanelli F, Ciampaglia W, Cognigni G . Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. J Endocrinol Invest. 2011; 34(9):685-91. DOI: 10.3275/7726. View

10.

Nisenblat V, Norman R . Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2009; 16(3):224-31. DOI: 10.1097/MED.0b013e32832afd4d. View

11.

Wheeler M . The determination of bio-available testosterone. Ann Clin Biochem. 1995; 32 ( Pt 4):345-57. DOI: 10.1177/000456329503200401. View

12.

Gonzalez F, Rote N, Minium J, Kirwan J . Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 91(1):336-40. DOI: 10.1210/jc.2005-1696. View

13.

Huang A, Brennan K, Azziz R . Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2009; 93(6):1938-41. PMC: 2859983. DOI: 10.1016/j.fertnstert.2008.12.138. View

14.

Wartofsky L, Handelsman D . Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab. 2010; 95(12):5141-3. DOI: 10.1210/jc.2010-2369. View

15.

Galluzzo A, Calogero Amato M, Giordano C . Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008; 18(7):511-8. DOI: 10.1016/j.numecd.2008.05.004. View

16.

Azziz R . Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005; 83(5):1343-6. DOI: 10.1016/j.fertnstert.2005.01.085. View

17.

Kuscu N, Var A . Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009; 88(5):612-7. DOI: 10.1080/00016340902859315. View

18.

Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T . Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999; 22(5):818-22. DOI: 10.2337/diacare.22.5.818. View

19.

Clark P . Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem. 1999; 36 ( Pt 5):541-64. DOI: 10.1177/000456329903600501. View

20.

Kauffman R, Baker V, DiMarino P, Castracane V . Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertil Steril. 2006; 85(4):1010-6. DOI: 10.1016/j.fertnstert.2005.09.046. View